boxed-warning compounded cost glp-1 mounjaro ozempic peptides precision-peptide-genetic-test regain safety saxenda semaglutide side-effects telehealth tirzepatide wegovy Weight Management weight-loss zepbound

May 05, 2026
24 MIN READ

Cons of GLP-1 (2026): Side Effects, Cost, Regain and What PlexusDx Does Differently | PlexusDx

An honest read on the cons of GLP-1 therapy — GI side effects, the boxed warning, cost, weight regain on cessation, and body composition — plus where PlexusDx Weight Management Protocols ($129–$325/mo, all 50 states, no membership) fit when insurance friction is itself one of the cons.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

May 05, 2026
24 MIN READ

Cons of GLP-1 medications — side effects, boxed warning, cost, and weight regain explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

GLP-1 receptor agonists are the most effective pharmacotherapy weight management has ever had — and they come with a real list of downsides that every cash-pay shopper should understand before signing up. Gastrointestinal side effects affect the majority of patients during titration. The thyroid C-cell tumor boxed warning applies to both semaglutide and tirzepatide. Trial data shows substantial weight regain after stopping. Insurance coverage for weight-loss GLP-1s remains spotty in 2026, and the FDA has flagged ongoing concerns with unverified compounded sources. This is a balanced read on the cons — and where the Microdose GLP-1 Protocol at $129/mo, Semaglutide Injection at $149/mo, and Tirzepatide Injection at $249/mo fit when insurance friction itself is one of the cons you're trying to avoid.

The cons at a glance — what every cash-pay shopper should know

Five categories cover the bulk of legitimate complaints about GLP-1 therapy. GI side effects — nausea, vomiting, diarrhea, constipation — show up in roughly half to three-quarters of patients during dose escalation per FDA labels. Serious but uncommon risks include pancreatitis, gallbladder disease, acute kidney injury (often dehydration-driven), and the boxed warning for thyroid C-cell tumors that applies to both semaglutide and tirzepatide based on rodent studies. Cost and access remains a barrier: most commercial insurance plans don't reliably cover GLP-1s for weight loss in 2026, branded list prices run roughly $1,000–$1,350/month, and shortages have repeatedly disrupted supply. Weight regain on cessation is well-documented — trial withdrawal data shows patients regain a meaningful share of their loss within a year. Body composition changes include lean-mass loss alongside fat loss, requiring a deliberate strength-training and protein strategy. None of these cons disqualify GLP-1 therapy for the right patient — they just need to be priced into the decision.

GI side effects — the most common con

Per the FDA Wegovy label, 73% of patients reported GI adverse reactions versus 47% on placebo, with nausea at 44%, diarrhea at 30%, vomiting at 25%, and constipation at 24%. The Zepbound label shows dose-dependent nausea at 25–29%, diarrhea at 19–23%, and constipation at 11–17%. Saxenda (liraglutide) reports nausea at 39.3% and diarrhea at 20.9%. Most GI events occur during dose escalation and improve after the dose stabilizes — which is why titration speed matters. A slower, longer titration trades a few extra weeks against a meaningfully better tolerability curve. PlexusDx protocols build in clinician-managed titration steps; Microdose GLP-1 Protocol at $129/mo is specifically designed for patients who prefer to start at a lower exposure level and ramp slowly, and the Semaglutide Injection protocol moves through five dose levels from 0.25mg to 2.0mg weekly. If GI symptoms get severe — can't keep fluids down, severe abdominal pain, signs of dehydration — that's a same-day clinical call, not a wait-it-out situation.

Serious risks — rare but real, and the boxed warning

The FDA labels for both semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) carry a boxed warning for thyroid C-cell tumors based on rodent studies showing increased incidence of medullary thyroid carcinoma in animals exposed to GLP-1 receptor agonists. Both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This applies to compounded semaglutide and tirzepatide too — same active ingredient, same warning. Pancreatitis is a labeled warning — severe abdominal pain (often radiating to the back) plus vomiting needs emergency evaluation. Gallbladder disease showed up in the trials at elevated rates: Wegovy reported cholelithiasis at 1.6% versus 0.7% on placebo and cholecystitis at 0.6% versus 0.2%. Acute kidney injury is uncommon but real, often driven by dehydration from severe nausea and vomiting. None of these are reasons to avoid GLP-1 therapy if you're an appropriate candidate — they're reasons to have a real prescriber, real titration discipline, and a clear plan for when to call.

Cost and access — when insurance friction is itself a con

FDA-approved branded GLP-1s for weight management run roughly $1,000–$1,350/month at list price. Lilly Direct's Zepbound self-pay vials price around $499/month for those who qualify. Wegovy savings cards reduce out-of-pocket cost for some commercially insured patients but exclude Medicare and Medicaid. Most commercial plans as of 2026 still don't cover GLP-1s for weight loss without a documented type-2 diabetes diagnosis, which means a large share of patients pay cash or don't start. That's where the cash-pay compounded route fits — not as a replacement for FDA-approved branded drugs when insurance covers them, but as a defined-cost alternative when it doesn't. PlexusDx Weight Management Protocols are all-inclusive: provider consultation, prescription, compounded medication, and shipping in one monthly bill. The Microdose GLP-1 Protocol runs $129/mo flat. Semaglutide Injection runs $149/mo across five dose levels. Tirzepatide Injection runs $249/mo across six dose levels. GLP-Squared, the dual-compound stack, runs $249/mo. There is no membership fee, no insurance, and the program operates in all 50 states (five require a scheduled live consult rather than async intake). Compounded semaglutide and tirzepatide are not FDA-approved finished products — they're pharmacy-prepared formulations of the same active ingredients, and the regulatory framework that governs them differs from the framework that governs Wegovy and Zepbound. That's a real distinction; it's also a fair trade for many cash-pay patients.

Weight regain on cessation — the long-term planning con

The most sobering trial data on GLP-1s isn't about side effects — it's about what happens when patients stop. The STEP-1 extension showed semaglutide patients regained roughly two-thirds of their lost weight within a year of discontinuation. Tirzepatide withdrawal data from SURMOUNT-4 showed patients who stopped regained approximately 14% of body weight, while those who continued lost an additional ~5%. The implication: GLP-1 therapy for obesity is closer to a chronic-management framework than a time-limited course. If you start, plan for ongoing therapy — or plan deliberately for a maintenance strategy that includes resistance training, protein sufficiency, sleep, and a tapered transition rather than abrupt cessation. This is also where genetic variability becomes practical: patients with certain GLP1R, FTO, MC4R, and TCF7L2 variants may respond differently to the same dose and may have different regain trajectories. The Precision Peptide Genetic Test — $298 standalone or $99 as an add-on after your first month on any protocol — maps 48 genes and 57 variants across 14 health pathways including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response. The test doesn't change the underlying biology, but it gives the prescribing clinician a real baseline to work from.

Drug interactions, pregnancy, surgery — the situational cons

Tirzepatide carries a specific interaction with oral contraceptives: it may reduce oral hormonal contraceptive efficacy. The label recommends backup or non-oral contraception for four weeks after initiation and after each dose increase. This is tirzepatide-specific — semaglutide does not carry the same warning. Pregnancy is a contraindication for all GLP-1s for weight management; Wegovy specifically advises stopping at least two months before a planned pregnancy due to the long half-life. Surgery and anesthesia planning has been updated repeatedly — current guidance is risk-based, with the anesthesia team informed of GLP-1 use because delayed gastric emptying raises aspiration risk. None of these are reasons to avoid GLP-1 therapy — they're reasons to coordinate with the rest of your care. PlexusDx clinicians review medication history and contraindications during intake; the GLP-Squared dual-compound protocol and Tirzepatide Injection protocol both flag the contraceptive interaction explicitly.

Body composition — what gets lost along with the fat

DXA substudies show roughly 25% of weight lost on GLP-1 therapy is lean mass, with significant individual variation. That ratio isn't fixed — it shifts meaningfully with deliberate resistance training and adequate protein intake (typically 1.2–1.6 g/kg body weight). Patients who lose weight without a strength-training plan often end up at a similar or worse body-composition outcome than where they started, even with a meaningfully lower scale weight. This is solvable with planning, not avoidance. The practical playbook: start a structured resistance program before or during initiation, prioritize protein at every meal, monitor lean mass via DXA or bioimpedance if available, and don't conflate lower scale weight with better metabolic health. The Optimal Diet & Weight Loss Genetic Test covers 295+ genetic insights across nutrition response, body composition, metabolism, and fitness — useful for shaping the strength and protein plan that runs alongside any GLP-1 protocol.

Compounded GLP-1s — understanding what you're actually buying

The FDA has raised significant concerns about quality, dosing errors, and adverse events with some compounded GLP-1 products — particularly products from unverified sources, non-licensed pharmacies, and "research peptide" sites. Those concerns are real and worth taking seriously. They are also separable from the question of whether licensed U.S. compounding pharmacies operating under state and federal compounding regulations are appropriate for cash-pay GLP-1 access. PlexusDx Weight Management Protocols use licensed U.S. compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products — we won't claim otherwise. They are pharmacy-prepared formulations of the same active ingredients found in Wegovy, Ozempic, Zepbound, and Mounjaro. The regulatory difference is real, the cost difference is meaningful, and the choice depends on what the patient values. If FDA-approved branded product is a non-negotiable, compounded routes — including PlexusDx's — aren't the right fit. If insurance friction has been the wall between you and a GLP-1 protocol, the cash-pay compounded route through a licensed pharmacy is a legitimate path worth comparing on its actual terms.

Frequently asked questions

What are the most common cons of GLP-1 medications?

Per FDA labels, GI side effects (nausea, vomiting, diarrhea, constipation) affect 50–73% of patients during titration. Cost and insurance access remain barriers, and weight regain on cessation is well-documented — trial data shows patients regain roughly two-thirds of lost weight within a year of stopping semaglutide. PlexusDx structures clinician-managed titration to ease the GI curve and prices the Microdose GLP-1 Protocol at $129/mo flat for patients who want a slower, lower-exposure entry.

Are GLP-1 drugs safe?

FDA-approved GLP-1s have been used by millions of patients and have well-characterized safety profiles. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Pancreatitis and gallbladder disease are labeled warnings. Safety depends on the patient's contraindications, comorbidities, and titration discipline — which is why a real prescribing clinician matters.

Do GLP-1 side effects go away?

Most patients see GI symptoms improve after dose stabilization, typically within a few weeks of holding at a steady dose. A slower titration meaningfully reduces the peak severity for many patients. Some have persistent symptoms that require switching to a lower dose, a different formulation, or discontinuing — that's a clinical decision worth making early rather than enduring symptoms that aren't going to resolve.

What happens when you stop taking a GLP-1?

Trial withdrawal data is the cleanest read. STEP-1 extension data showed semaglutide patients regained roughly two-thirds of their lost weight within a year of stopping. Tirzepatide withdrawal data from SURMOUNT-4 showed patients regained around 14% of body weight after discontinuation. Plan for ongoing therapy or a deliberate maintenance strategy — abrupt cessation without a plan tends to undo a meaningful share of the progress.

Does tirzepatide affect birth control?

Yes — tirzepatide may reduce the efficacy of oral hormonal contraceptives. The FDA label recommends backup contraception or a non-oral method (IUD, implant, injection) for four weeks after initiation and after each dose increase. This is tirzepatide-specific; semaglutide does not carry the same warning. PlexusDx Tirzepatide Injection intake reviews this with patients before titration.

Are compounded GLP-1s a legitimate option?

Compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies are pharmacy-prepared formulations of the same active ingredients in Wegovy and Zepbound. They are not FDA-approved finished drug products — that distinction is real and worth understanding. The FDA has flagged concerns with unverified sources and "research peptide" sites, which is why source matters. PlexusDx uses licensed U.S. compounding pharmacies and prices protocols from $129/mo for a defined cash-pay path.

Can a genetic test help me decide on a GLP-1 dose?

The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways, including 34 weight-management insights and the GIPR rs1800437 variant associated with differential GLP-1 response. It doesn't replace clinical judgment, but it gives the prescribing clinician a measurable baseline to anchor titration and choice between semaglutide and tirzepatide. It's $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves